Granted Patent
B2
US 8,552,193 · App. 12/750,777 · Granted Oct 8, 2013
Alternative forms of the phosphodiesterase-4 inhibitor N-cyclopropyl-1-{3-[(1-oxidopryidin-3-yl)ethynyl]phenyl}-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxyamide
Inventors:
Sophie-Dorothee Clas (Montreal, CA); Rafik Naccache (Laval, CA); Hongshi Yu (Dollard-des-Ormeaux, CA); Jerry Murry (New York, NY); Narayan Vanankaval (Plainsboro, NJ)
Assignee:
Merck Sharp & Dohme Corp.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention is directed to alternative forms of the title phosphodiesterase 4 inhibitor which has the structural formula shown immediately below:
Claims (4)
1. The hemihydrate of the compound IX
which is designated Form VI.
2. The Form VI, a hemihydrate of the compound IX, according to claim 1 , wherein the Form VI has characteristic reflection peaks at 6.0, 15.3, 15.9, 23.8 and 25.0 degrees 2θ determined by x-ray powder diffraction.
3. A pharmaceutical composition comprising a non-toxic therapeutic amount of a Form VI, the hemihydrate, according to claim 1 and a pharmaceutically acceptable carrier.
Assignments (1)
MERGER
Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
Continuity (4)
Division
11547916
Provisional Application
60565446
· Apr 26, 2004
Related Publication
20130231363A9
· Sep 5, 2013